|
Generalized Anxiety Disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Major depressive disorders (MDD) and generalized anxiety disorders (GAD) were diagnosed in 2006 and 2010 using the Mini International Neuropsychiatric Interview among 5684 workers from the French SIP cohort.
|
31377852 |
2020 |
|
Major Depressive Disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Major depressive disorders (MDD) and generalized anxiety disorders (GAD) were diagnosed in 2006 and 2010 using the Mini International Neuropsychiatric Interview among 5684 workers from the French SIP cohort.
|
31377852 |
2020 |
|
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Given the same baseline status for SIP-D and ASSIST, respectively, those with anxiety or depression had greater increases in SIP-D (adjusted mean difference [95% confidence interval] +3.26 [1.20; 5.32], P = 0.004) and borderline significant increases in ASSIST (+3.27 [-0.12; 6.65], P = 0.06) compared with those without anxiety or depression; those with both anxiety and depression had greater increases in ASSIST (+5.42 [2.05; 8.79], P = 0.003), but not SIP-D (+1.80 [-0.46; 4.06], P = 0.12).
|
28984682 |
2019 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Given the same baseline status for SIP-D and ASSIST, respectively, those with anxiety or depression had greater increases in SIP-D (adjusted mean difference [95% confidence interval] +3.26 [1.20; 5.32], P = 0.004) and borderline significant increases in ASSIST (+3.27 [-0.12; 6.65], P = 0.06) compared with those without anxiety or depression; those with both anxiety and depression had greater increases in ASSIST (+5.42 [2.05; 8.79], P = 0.003), but not SIP-D (+1.80 [-0.46; 4.06], P = 0.12).
|
28984682 |
2019 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Reduced nNOS expression in enteric inhibitory motor neurons and/or reduced connectivity between nNOS<sup>+</sup> neurons and the SIP syncytium appear to be responsible for motor defects that develop in diabetes.
|
30063800 |
2019 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
Reduced nNOS expression in enteric inhibitory motor neurons and/or reduced connectivity between nNOS<sup>+</sup> neurons and the SIP syncytium appear to be responsible for motor defects that develop in diabetes.
|
30063800 |
2019 |
|
Age-related cataract
|
0.010 |
Biomarker
|
disease |
BEFREE |
SUMOylation Evoked by Oxidative Stress Reduced Lens Epithelial Cell Antioxidant Functions by Increasing the Stability and Transcription of TP53INP1 in Age-Related Cataracts.
|
31281592 |
2019 |
|
B-Cell Lymphomas
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The protein and mRNA expression levels of TP53INP1, B-cell lymphoma 2 (Bcl-2)-associated-X and p21 were significantly increased, whereas those of Bcl-2 were significantly decreased in the miR-3934-5p inhibitor group, which was significantly reduced by TP53INP1 siRNA transfection. miR-3934-5p, as a tumor suppressor in NSCLC, may promote the sensitivity of cells to DDP by targeting TP53INP1, associated with the suppression of cell proliferation and promotion of apoptosis.
|
31410122 |
2019 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphoma.
|
31565482 |
2019 |
|
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Given the same baseline status for SIP-D and ASSIST, respectively, those with anxiety or depression had greater increases in SIP-D (adjusted mean difference [95% confidence interval] +3.26 [1.20; 5.32], P = 0.004) and borderline significant increases in ASSIST (+3.27 [-0.12; 6.65], P = 0.06) compared with those without anxiety or depression; those with both anxiety and depression had greater increases in ASSIST (+5.42 [2.05; 8.79], P = 0.003), but not SIP-D (+1.80 [-0.46; 4.06], P = 0.12).
|
28984682 |
2019 |
|
Marijuana Use
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mean (SD) number of marijuana use days was 16.4 (11.6), mean SIP-D 5.9 (9.0), mean ASSIST 12.5 (7.8); no significant association was found between anxiety/depression and marijuana use changes.
|
28984682 |
2019 |
|
Mantle cell lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphoma.
|
31565482 |
2019 |
|
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
According to these preliminary data, VRT with I-SIP can be considered a useful complementary treatment to potentiate functional recovery, with regard to attention, visual-spatial deficits, and motor function in patients affected by stroke.
|
29148855 |
2018 |
|
Varicosity
|
0.010 |
Biomarker
|
disease |
BEFREE |
ICC-DMP lie in close proximity to the varicosities of motor neurons and generate ongoing Ca<sup>2+</sup> transients that underlie activation of Ca<sup>2+</sup>-dependent Cl<sup>-</sup> channels and regulate the excitability of SMCs in the SIP syncytium.
|
29686622 |
2018 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
In an effort to explore possible molecular links between T2DM and AD, the present study investigated the status of neurodegeneration, adult hippocampal neurogenesis, and nitrosative stress induced protein S-nitrosylation in streptozotocin (STZ) induced mice models of T2DM.
|
29147492 |
2017 |
|
Ependymoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We propose miR-124-3p and TP53INP1 as new biomarkers for prognostic stratification that may be possible therapeutic targets for ependymoma.
|
28437838 |
2017 |
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Downregulated DEGs included TFs, such as the proto‑oncogene SPI1, pre‑B‑cell leukemia homeobox 3 (PBX3) and lymphoid enhancer‑binding factor 1 (LEF1), as well as tumor suppressors (TSs), such as capping actin protein, gelsolin like (CAPG) and tumor protein p53‑inducible nuclear protein 1 (TP53INP1).
|
28791367 |
2017 |
|
Common ventricle
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
137 infants <1 year with SV with SIP undergoing care from January 2008 to June 2015 were retrospectively evaluated.
|
28770308 |
2017 |
|
Adult Ependymoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We propose miR-124-3p and TP53INP1 as new biomarkers for prognostic stratification that may be possible therapeutic targets for ependymoma.
|
28437838 |
2017 |
|
Newly Diagnosed Childhood Ependymoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We propose miR-124-3p and TP53INP1 as new biomarkers for prognostic stratification that may be possible therapeutic targets for ependymoma.
|
28437838 |
2017 |
|
Childhood Ependymoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma.
|
28437838 |
2017 |
|
Single Ventricle Defect
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
137 infants <1 year with SV with SIP undergoing care from January 2008 to June 2015 were retrospectively evaluated.
|
28770308 |
2017 |
|
Bodily Pain
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
120 severely fatigued patients with type 1 diabetes completed questionnaires on pain (McGill Pain Questionnaire, MPQ; Short Form Health Survey subscale bodily pain, SF-36), fatigue severity (Checklist Individual Strength subscale fatigue severity, CIS), depressive symptoms (Beck Depression Inventory Primary Care, BDI-PC) and functional impairment (Sickness Impact Profile-8, SIP-8).
|
28314551 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of CacyBP/SIP expression in CLL patients was negatively correlated with CLL clinical stage, but not with patient sex, age, del(13q14) or del(17q-) presence, or ZAP-70 expression.
|
26603518 |
2016 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
The miR-205/TP53INP1 mediated autophagy pathway might be an important molecular mechanism regulating radiosensitivity of prostate cancer cells and represents a potential therapeutic target for prostate cancer.
|
26813458 |
2016 |